Market summary
Friday's session is mixed with the Nasdaq under pressure from chip-stock losses (Intel, Micron, and AI infrastructure names all sliding), while defensive and earnings-driven names lead the tape. Geopolitical angst around Iran and fresh tariffs are adding late-session volatility, with breadth narrowing into a few standout earnings winners.
Executed
Rejected by validator
Watch notes
Watching SMCI for stabilization — its record $60B backlog and gross margin raise are fundamentally bullish, but the chip-sector downdraft is masking the story; if it holds $28-30 support I may add. NU remains a core hold near breakeven with the Mexico bank launch tracking well. ABT's Baird initiation and undervaluation narrative keep me patient with the +4.12% gain. On the watchlist for next run: THC and RNG are earnings rockets I missed today but chasing 17-25% gap-ups is risky; better to see how they consolidate. HIMS is interesting on the FDA peptide panel news if it pulls back from the -12.16% overreaction.
Raw model output
{
"market_summary": "Friday's session is mixed with the Nasdaq under pressure from chip-stock losses (Intel, Micron, and AI infrastructure names all sliding), while defensive and earnings-driven names lead the tape. Geopolitical angst around Iran and fresh tariffs are adding late-session volatility, with breadth narrowing into a few standout earnings winners.",
"decisions": [
{
"action": "SELL",
"ticker": "NVCR",
"shares": 7,
"reasoning": "NVCR is down 8.50% today on heavy volume despite what headlines call its 'strongest quarter ever,' a classic sell-the-news reaction that has broken the momentum thesis I bought into. The stock is now my worst performer at -8.60% unrealized, and the sharp reversal from the 1M +34.39% rally suggests the post-earnings rally has exhausted itself. With Wedbush only maintaining a $20 price target — barely above the current $18.29 — the risk/reward has deteriorated. I am cutting the full 7-share position to free up ~$128 of capital and redeploy into higher-conviction setups where the catalyst is fresh rather than fading."
},
{
"action": "BUY",
"ticker": "DLR",
"shares": 2,
"reasoning": "Digital Realty just gapped up 11.83% on a huge Q2 FFO beat and raised 2026 guidance driven by leasing strength and renewal rent growth, making it one of the strongest fundamental catalysts on the tape today. As a data center REIT, DLR sits at the intersection of AI infrastructure demand and defensive income, a sector rotation that fits the current risk-off mood in semis. At $200.56, two shares cost ~$401, well within my $459 spendable budget and the 15% position cap ($150.43 max — I am intentionally under-sizing given the price). I am buying the post-earnings momentum with a fresh catalyst rather than chasing extended runners."
}
],
"watch_notes": "Watching SMCI for stabilization — its record $60B backlog and gross margin raise are fundamentally bullish, but the chip-sector downdraft is masking the story; if it holds $28-30 support I may add. NU remains a core hold near breakeven with the Mexico bank launch tracking well. ABT's Baird initiation and undervaluation narrative keep me patient with the +4.12% gain. On the watchlist for next run: THC and RNG are earnings rockets I missed today but chasing 17-25% gap-ups is risky; better to see how they consolidate. HIMS is interesting on the FDA peptide panel news if it pulls back from the -12.16% overreaction."
}